Trials / Completed
CompletedNCT03725072
Human Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-Evobrutinib
Phase I, Open Label, Single Dose Study to Determine the Pharmacokinetics, Metabolism, and Excretion of [14C]-Evobrutinib in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Merck KGaA, Darmstadt, Germany · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to determine the absorption, metabolism, and excretion of \[14C\]-evobrutinib in healthy participants
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Evobrutinib | Participants will receive a single, oral dose of evobrutinib under fasting conditions as a solution, which will contain \[14C\]-evobrutinib. |
Timeline
- Start date
- 2018-10-30
- Primary completion
- 2018-12-05
- Completion
- 2018-12-05
- First posted
- 2018-10-30
- Last updated
- 2020-07-07
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT03725072. Inclusion in this directory is not an endorsement.